Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00885534CT.gov Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00002882CT.gov Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Skin Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vinblastine (this asset) | Memorial Sloan Kettering Cancer Center | P3 | BB · 64 |
| Prednisone | Dana-Farber Cancer Institute | P4 | BBB |
| Cyclophosphamide | Institute of Oncology Ljubljana | P2 | BB |
| Sirolimus | Dana-Farber Cancer Institute | P4 | BB |
| Nivolumab | 7 Hills Pharma, LLC | P3 | BB |
| Fludarabine | H. Lee Moffitt Cancer Center and Research Institute | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Toray Industries, Inc | P3 | BB |
| Dacarbazine | Memorial Sloan Kettering Cancer Center | P3 | BB |
| TIL | H. Lee Moffitt Cancer Center and Research Institute | P2 | B |
+41 more in the Skin Cancer cohort
Other indications for Vinblastine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Pelvis/Ureter Urothelial Carcinoma | — | P3 | BBB · 73 |
| Carcinoma Of Urethra | — | P3 | BBB · 73 |
| Hodgkins Lymphoma | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vinblastine in Skin Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vinblastine-skin-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →